董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Sinkule | 男 | Chairman and Chief Executive Officer | 72 | 56.50万 | 734.67 | 2026-03-31 |
| Riad El Dada | 男 | Independent Director | 61 | 4.80万 | 41.00 | 2026-03-31 |
| Jon W. McGarity | 男 | Independent Director | 84 | 8.20万 | 47.13 | 2026-03-31 |
| Shalom Z. Hirschman | 男 | Independent Director | 89 | 14.50万 | 90.89 | 2026-03-31 |
| Samuel Zentman | 男 | Independent Director | 79 | 8.20万 | 114.64 | 2026-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Sinkule | 男 | Chairman and Chief Executive Officer | 72 | 56.50万 | 734.67 | 2026-03-31 |
| Jeffrey LeBlanc | 男 | Chief Financial Officer | 49 | 103.26万 | 未持股 | 2026-03-31 |
董事简历
中英对照 | 中文 | 英文- Joseph Sinkule
-
Joseph Sinkule已经从一名化学家、科学家和临床研究人员发展成为一名成功的商人和连续创业者。2015年，他创立并一直担任ANEW Oncology，Inc.的首席执行官和董事长。2022年，Sinkule博士成为收购ANEW Oncology的ANEW MEDICAL的董事长和首席执行官。1976年获得美国内布拉斯加州大学化学学士学位，1980年获得美国内布拉斯加州大学医学中心药学、药理学和药代动力学（Pharm.D.）博士学位。他的博士后培训是在田纳西州孟菲斯的圣裘德儿童研究医院，他在芝加哥大学和密歇根大学担任过多个学术职位。他于1990年加入制药和生物技术行业，曾担任关键管理层和高级董事职务超过15年，其中包括Techniclone International的高级副总裁和董事会成员，该公司是一家在33岁时在纳斯达克上市的生物技术公司。他创立、担任CEO，并在两家生物制药公司的董事会任职—— 2005年至2008年的Virionics Corporation和2008年至2012年的Apthera，Inc.。他于2015年创立并担任ANEW Oncology，Inc.的首席执行官和董事会主席，该公司于2019年成为ANEW MEDICAL，INC.。Joseph在过去40年里一直参与药物开发。在过去的18年里，他一直是细胞和基因治疗领域多家公司和学者的顾问和顾问。Sinkule博士还是公司治理委员会主席。Sinkule博士因其丰富的管理经验、药物开发经验、商业、金融和创业经验，以及国际人脉和关系，有资格担任Greenland Mines Ltd的董事会成员。
Joseph Sinkule has evolved from a chemist, scientist and clinical researcher into a successful businessman and serial entrepreneur. In 2015, he founded and has served as Chief Executive Officer and Chairman of Anew Oncology, Inc. In 2022, Dr. Sinkule became the Chairman and Chief Executive Officer of ANEW MEDICAL which acquired Anew Oncology. He received his B.S in Chemistry from the University of Nebraska in 1976 and a doctorate in pharmacy, pharmacology, and pharmacokinetics (Pharm.D.) from University of Nebraska Medical Center in 1980. His post doctoral training was at St. Jude Children's Research Hospital in Memphis, TN and he held several academic positions at the University of Chicago and the University of Michigan. He joined the pharmaceutical and biotechnology industry in 1990 and held key management and senior directorship positions for over 15 years including Senior Vice President and Board member of Techniclone International, a Nasdaq listed biotech company at the age of 33 years old. He founded, was the CEO, and served on the Board of two biopharmaceutical companies — Virionics Corporation from 2005 2008 and Apthera, Inc. from 2008 2012. He founded and served as CEO and Chairman of the Board of Anew Oncology, Inc. in 2015, which became ANEW MEDICAL, INC. in 2019. Joseph has been involved with drug development for the past 40 years. He has been a consultant and advisor to several companies and academics in the fields of cell and gene therapy for the past 18 years. Dr. Sinkule is also the Chair of the Corporate Governance Committee. - Joseph Sinkule已经从一名化学家、科学家和临床研究人员发展成为一名成功的商人和连续创业者。2015年，他创立并一直担任ANEW Oncology，Inc.的首席执行官和董事长。2022年，Sinkule博士成为收购ANEW Oncology的ANEW MEDICAL的董事长和首席执行官。1976年获得美国内布拉斯加州大学化学学士学位，1980年获得美国内布拉斯加州大学医学中心药学、药理学和药代动力学（Pharm.D.）博士学位。他的博士后培训是在田纳西州孟菲斯的圣裘德儿童研究医院，他在芝加哥大学和密歇根大学担任过多个学术职位。他于1990年加入制药和生物技术行业，曾担任关键管理层和高级董事职务超过15年，其中包括Techniclone International的高级副总裁和董事会成员，该公司是一家在33岁时在纳斯达克上市的生物技术公司。他创立、担任CEO，并在两家生物制药公司的董事会任职—— 2005年至2008年的Virionics Corporation和2008年至2012年的Apthera，Inc.。他于2015年创立并担任ANEW Oncology，Inc.的首席执行官和董事会主席，该公司于2019年成为ANEW MEDICAL，INC.。Joseph在过去40年里一直参与药物开发。在过去的18年里，他一直是细胞和基因治疗领域多家公司和学者的顾问和顾问。Sinkule博士还是公司治理委员会主席。Sinkule博士因其丰富的管理经验、药物开发经验、商业、金融和创业经验，以及国际人脉和关系，有资格担任Greenland Mines Ltd的董事会成员。
- Joseph Sinkule has evolved from a chemist, scientist and clinical researcher into a successful businessman and serial entrepreneur. In 2015, he founded and has served as Chief Executive Officer and Chairman of Anew Oncology, Inc. In 2022, Dr. Sinkule became the Chairman and Chief Executive Officer of ANEW MEDICAL which acquired Anew Oncology. He received his B.S in Chemistry from the University of Nebraska in 1976 and a doctorate in pharmacy, pharmacology, and pharmacokinetics (Pharm.D.) from University of Nebraska Medical Center in 1980. His post doctoral training was at St. Jude Children's Research Hospital in Memphis, TN and he held several academic positions at the University of Chicago and the University of Michigan. He joined the pharmaceutical and biotechnology industry in 1990 and held key management and senior directorship positions for over 15 years including Senior Vice President and Board member of Techniclone International, a Nasdaq listed biotech company at the age of 33 years old. He founded, was the CEO, and served on the Board of two biopharmaceutical companies — Virionics Corporation from 2005 2008 and Apthera, Inc. from 2008 2012. He founded and served as CEO and Chairman of the Board of Anew Oncology, Inc. in 2015, which became ANEW MEDICAL, INC. in 2019. Joseph has been involved with drug development for the past 40 years. He has been a consultant and advisor to several companies and academics in the fields of cell and gene therapy for the past 18 years. Dr. Sinkule is also the Chair of the Corporate Governance Committee.
- Riad El Dada
-
Riad El Dada是一位经验丰富的医疗保健高管，拥有全球经验。他目前是MKG集团的董事会成员，并且是默沙东 Sharp & Dohme联邦信用合作社的董事会董事。他是马林克罗制药的前任董事。El Dada先生还担任生命科学行业投资者和公司的顾问和顾问。他曾担任默沙东的高级主管，曾在美国、全球和国际经验丰富的领先组织任职，专注于创新药物的商业化。El Dada先生最近在默沙东担任的职务是美国总裁。他领导的商业团队在十几个治疗领域工作，收入超过120亿美元。在担任美国总统之前，El Dada先生是MSD在澳大利亚和新西兰的董事总经理。除了产品商业化，他在医药产品开发和生命周期管理方面拥有丰富的经验。在默沙东的职业生涯中，他谈判了几笔交易，并在许多合作伙伴关系中工作，跨越了开发和商业化的所有阶段。在加入默沙东之前，El Dada先生是麦肯锡的顾问。他曾在医疗保健和其他行业为多家财富500强客户服务。他是华盛顿特区医疗保健领导委员会的成员，2018年至2021年期间活跃在国会山。El Dada先生以优异成绩在康奈尔大学完成了本科学位。他还以优异的成绩获得了乔治城大学的研究生学位。
Riad El Dada is a seasoned healthcare executive with global experience. He is currently a member of the Board of Directors of The MKG Group and is a Board Director for the Merck Sharp & Dohme Federal Credit Union. He is a former Director of Mallinckrodt Pharmaceuticals. Mr. El Dada also serves as an advisor and consultant to investors and companies operating in the life sciences industry. He is a former Senior Executive at Merck with US, global and international experience leading organizations focused on the commercialization of innovative pharmaceuticals. In his most recent position at Merck, Mr. El Dada was President of the US. He led commercial teams working in a dozen therapeutic areas accounting for over $12 billion of revenue. Prior to assuming the role of US President, Mr. El Dada was the Managing Director for MSD in Australia & New Zealand. In addition to product commercialization, he has extensive experience in pharmaceutical product development and lifecycle management. Over his career at Merck, he negotiated several deals and worked in many partnerships across all phases of development and commercialization. Before joining Merck, Mr. El Dada was a consultant at McKinsey. He worked for a variety of Fortune 500 clients in healthcare and other industries. He was a member of the Healthcare Leadership Council in Washington, DC and was active on Capitol Hill from 2018 to 2021. Mr. El Dada completed his undergraduate degree at Cornell University Summa Cum Laude. He also earned a graduate degree with Distinction from Georgetown University. - Riad El Dada是一位经验丰富的医疗保健高管，拥有全球经验。他目前是MKG集团的董事会成员，并且是默沙东 Sharp & Dohme联邦信用合作社的董事会董事。他是马林克罗制药的前任董事。El Dada先生还担任生命科学行业投资者和公司的顾问和顾问。他曾担任默沙东的高级主管，曾在美国、全球和国际经验丰富的领先组织任职，专注于创新药物的商业化。El Dada先生最近在默沙东担任的职务是美国总裁。他领导的商业团队在十几个治疗领域工作，收入超过120亿美元。在担任美国总统之前，El Dada先生是MSD在澳大利亚和新西兰的董事总经理。除了产品商业化，他在医药产品开发和生命周期管理方面拥有丰富的经验。在默沙东的职业生涯中，他谈判了几笔交易，并在许多合作伙伴关系中工作，跨越了开发和商业化的所有阶段。在加入默沙东之前，El Dada先生是麦肯锡的顾问。他曾在医疗保健和其他行业为多家财富500强客户服务。他是华盛顿特区医疗保健领导委员会的成员，2018年至2021年期间活跃在国会山。El Dada先生以优异成绩在康奈尔大学完成了本科学位。他还以优异的成绩获得了乔治城大学的研究生学位。
- Riad El Dada is a seasoned healthcare executive with global experience. He is currently a member of the Board of Directors of The MKG Group and is a Board Director for the Merck Sharp & Dohme Federal Credit Union. He is a former Director of Mallinckrodt Pharmaceuticals. Mr. El Dada also serves as an advisor and consultant to investors and companies operating in the life sciences industry. He is a former Senior Executive at Merck with US, global and international experience leading organizations focused on the commercialization of innovative pharmaceuticals. In his most recent position at Merck, Mr. El Dada was President of the US. He led commercial teams working in a dozen therapeutic areas accounting for over $12 billion of revenue. Prior to assuming the role of US President, Mr. El Dada was the Managing Director for MSD in Australia & New Zealand. In addition to product commercialization, he has extensive experience in pharmaceutical product development and lifecycle management. Over his career at Merck, he negotiated several deals and worked in many partnerships across all phases of development and commercialization. Before joining Merck, Mr. El Dada was a consultant at McKinsey. He worked for a variety of Fortune 500 clients in healthcare and other industries. He was a member of the Healthcare Leadership Council in Washington, DC and was active on Capitol Hill from 2018 to 2021. Mr. El Dada completed his undergraduate degree at Cornell University Summa Cum Laude. He also earned a graduate degree with Distinction from Georgetown University.
- Jon W. McGarity
-
Jon W. McGarity是EthiX Associates的总裁兼首席执行官，EthiX Associates成立于1996年2月，是一家服务于医疗保健行业业务需求的咨询公司，重点关注制药和生物技术。此外，自2022年以来，他一直担任MiClimate，Inc.的首席运营官，该公司开发了第一个体温调节设备，从而改变了人们管理个人温度敏感性的方式。他共同创立了NeuroEM Therapeutics，Inc.，该公司目前正在评估经颅电磁疗法（TEMT）用于治疗阿尔茨海默病患者的认知功能，自2021年以来一直担任其首席商务官。此外，他目前是亚利桑那州立大学生物设计研究所的顾问。他是亚利桑那州生物科学路线图委员会的原始成员和现任成员，该委员会为亚利桑那州的生物科学行业提供战略方向。他的制药经验包括在葛兰素史克、百时美施贵宝和诺华（山德士制药）担任高级管理职位。McGarity先生已经推出了40多种产品，并完成了许多涉及产品收购、许可、共同营销和促销安排的业务发展交易。
Jon W. McGarity is the President & CEO of EthiX Associates, which he founded in February 1996 and is a consultancy business serving the business needs of the healthcare industry with a focus on pharmaceuticals and biotechnology. In addition, he has been the Chief Operating Officer of MiClimate, Inc. since 2022 which has developed the first body temperature regulation device resulting in a change in the way people manage individual temperature sensitivities. He co founded NeuroEM Therapeutics, Inc., which is currently evaluating transcranial electromagnetic therapy (TEMT) for the treatment of cognitive functioning in Alzheimer's disease patients, and has been its Chief Business Officer since 2021. In addition, he currently is an Advisor to the Biodesign Institute at Arizona State University. He is an original and current member of the Arizona Biosciences Roadmap Committee which provides strategic direction to the biosciences industry in Arizona. His pharmaceutical experience includes senior management positions with GlaxoSmithKline, Bristol Myers Squibb, and Novartis (Sandoz Pharmaceuticals). Mr. McGarity has launched over 40 products as well as completing numerous business development deals involving product acquisitions, licensing, co marketing and promotional arrangements. - Jon W. McGarity是EthiX Associates的总裁兼首席执行官，EthiX Associates成立于1996年2月，是一家服务于医疗保健行业业务需求的咨询公司，重点关注制药和生物技术。此外，自2022年以来，他一直担任MiClimate，Inc.的首席运营官，该公司开发了第一个体温调节设备，从而改变了人们管理个人温度敏感性的方式。他共同创立了NeuroEM Therapeutics，Inc.，该公司目前正在评估经颅电磁疗法（TEMT）用于治疗阿尔茨海默病患者的认知功能，自2021年以来一直担任其首席商务官。此外，他目前是亚利桑那州立大学生物设计研究所的顾问。他是亚利桑那州生物科学路线图委员会的原始成员和现任成员，该委员会为亚利桑那州的生物科学行业提供战略方向。他的制药经验包括在葛兰素史克、百时美施贵宝和诺华（山德士制药）担任高级管理职位。McGarity先生已经推出了40多种产品，并完成了许多涉及产品收购、许可、共同营销和促销安排的业务发展交易。
- Jon W. McGarity is the President & CEO of EthiX Associates, which he founded in February 1996 and is a consultancy business serving the business needs of the healthcare industry with a focus on pharmaceuticals and biotechnology. In addition, he has been the Chief Operating Officer of MiClimate, Inc. since 2022 which has developed the first body temperature regulation device resulting in a change in the way people manage individual temperature sensitivities. He co founded NeuroEM Therapeutics, Inc., which is currently evaluating transcranial electromagnetic therapy (TEMT) for the treatment of cognitive functioning in Alzheimer's disease patients, and has been its Chief Business Officer since 2021. In addition, he currently is an Advisor to the Biodesign Institute at Arizona State University. He is an original and current member of the Arizona Biosciences Roadmap Committee which provides strategic direction to the biosciences industry in Arizona. His pharmaceutical experience includes senior management positions with GlaxoSmithKline, Bristol Myers Squibb, and Novartis (Sandoz Pharmaceuticals). Mr. McGarity has launched over 40 products as well as completing numerous business development deals involving product acquisitions, licensing, co marketing and promotional arrangements.
- Shalom Z. Hirschman
-
Shalom Z. Hirschman作为一名学术医生、研究科学家、教育家，以及最近的生物技术企业家和顾问，有着很长的职业生涯。Hirschman博士曾在哈佛医学院麻省总医院担任实习医生和住院医师。在美国国立卫生研究院（NIH）进行了多年的分子生物学和分子病毒学研究后，他被招募到世界著名的西奈山医学院创始学院，在那里他被任命为感染性疾病学部主任和医学教授。赫希曼博士曾在西奈山医学院和西奈山医院担任过三十年的感染科主任，此外还担任过多年的医学系副主席。赫希曼博士在西奈山任职期间对医学研究的众多贡献包括发现了乙型肝炎病毒（HBV）的DNA聚合酶、对病毒DNA的表征、HBV在细胞培养中的成功复制以及首次将艾滋病描述为一种免疫性疾病。赫希曼博士还曾担任副主席，随后担任纽约科学院微生物学部门主席。他从西奈山退休，并加入Advanced Viral Research Corp.，担任其首席执行官、总裁和首席科学官。在那里，他成功地创造了一种新型的基于多肽的药物，建造了FDA批准的制造设施，并将这种药物带入了与美国FDA的IND下的临床试验。随后，他在图罗学院和图罗大学系统担任研究生和专业教育高级副总裁和研究生学术事务高级副总裁。Hirschman博士是图罗学院和图罗大学系统的三位创始人之一，曾担任董事会成员超过三十年。他发起并谈判由图罗学院购买纽约医学院。在过去五年中，Hirschman博士一直是教育机构、生物技术公司和生物技术投资基金的顾问，特别是Sunrise Securities Corporation的顾问。
Shalom Z. Hirschman has had a long career as an academic physician, research scientist, educator, and, most recently, biotechnology entrepreneur and consultant. Dr. Hirschman served as intern and resident in medicine at The Massachusetts General Hospital of the Harvard Medical School. Following years of research in molecular biology and molecular virology at the National Institutes of Health (NIH), he was recruited to the world renowned founding faculty of The Mount Sinai School of Medicine where he was appointed as Director of the Division of Infectious Diseases and Professor of Medicine. Dr. Hirschman served for three decades as Director of the Division of Infectious Diseases, and, in addition, for many years as Vice Chairman of the Department of Medicine, at The Mount Sinai School of Medicine and The Mount Sinai Hospital. Included among Dr. Hirschman's many contributions to medical research during his tenure at Mt. Sinai are the discovery of the DNA polymerase of the hepatitis B virus (HBV), the characterization of the viral DNA, the successful replication of HBV in cell culture and the first description of AIDS as an immunologic disease. Dr. Hirschman also served as Vice Chairman and then as Chairman of the Microbiology Section of the New York Academy of Sciences. He retired from Mount Sinai and joined Advanced Viral Research Corp. as its Chief Executive Officer, President, and Chief Scientific Officer. There he successfully created a new type of peptide based drug, built an FDA approved manufacturing facility, and brought this drug into clinical trials under INDs with the US FDA. He then took the positions as Senior Vice President for Graduate and Professional Education and Senior Vice President for Graduate Academic Affairs at Touro College and the Touro University System. Dr. Hirschman is one of the three founders of Touro College and the Touro University System and served as a member of the Board of Directors for more than three decades. He initiated and negotiated the purchase of New York Medical College by Touro College. During the past five years Dr. Hirschman has been a consultant to educational institutions, biotechnology companies and biotechnology investment funds, especially to Sunrise Securities Corporation. - Shalom Z. Hirschman作为一名学术医生、研究科学家、教育家，以及最近的生物技术企业家和顾问，有着很长的职业生涯。Hirschman博士曾在哈佛医学院麻省总医院担任实习医生和住院医师。在美国国立卫生研究院（NIH）进行了多年的分子生物学和分子病毒学研究后，他被招募到世界著名的西奈山医学院创始学院，在那里他被任命为感染性疾病学部主任和医学教授。赫希曼博士曾在西奈山医学院和西奈山医院担任过三十年的感染科主任，此外还担任过多年的医学系副主席。赫希曼博士在西奈山任职期间对医学研究的众多贡献包括发现了乙型肝炎病毒（HBV）的DNA聚合酶、对病毒DNA的表征、HBV在细胞培养中的成功复制以及首次将艾滋病描述为一种免疫性疾病。赫希曼博士还曾担任副主席，随后担任纽约科学院微生物学部门主席。他从西奈山退休，并加入Advanced Viral Research Corp.，担任其首席执行官、总裁和首席科学官。在那里，他成功地创造了一种新型的基于多肽的药物，建造了FDA批准的制造设施，并将这种药物带入了与美国FDA的IND下的临床试验。随后，他在图罗学院和图罗大学系统担任研究生和专业教育高级副总裁和研究生学术事务高级副总裁。Hirschman博士是图罗学院和图罗大学系统的三位创始人之一，曾担任董事会成员超过三十年。他发起并谈判由图罗学院购买纽约医学院。在过去五年中，Hirschman博士一直是教育机构、生物技术公司和生物技术投资基金的顾问，特别是Sunrise Securities Corporation的顾问。
- Shalom Z. Hirschman has had a long career as an academic physician, research scientist, educator, and, most recently, biotechnology entrepreneur and consultant. Dr. Hirschman served as intern and resident in medicine at The Massachusetts General Hospital of the Harvard Medical School. Following years of research in molecular biology and molecular virology at the National Institutes of Health (NIH), he was recruited to the world renowned founding faculty of The Mount Sinai School of Medicine where he was appointed as Director of the Division of Infectious Diseases and Professor of Medicine. Dr. Hirschman served for three decades as Director of the Division of Infectious Diseases, and, in addition, for many years as Vice Chairman of the Department of Medicine, at The Mount Sinai School of Medicine and The Mount Sinai Hospital. Included among Dr. Hirschman's many contributions to medical research during his tenure at Mt. Sinai are the discovery of the DNA polymerase of the hepatitis B virus (HBV), the characterization of the viral DNA, the successful replication of HBV in cell culture and the first description of AIDS as an immunologic disease. Dr. Hirschman also served as Vice Chairman and then as Chairman of the Microbiology Section of the New York Academy of Sciences. He retired from Mount Sinai and joined Advanced Viral Research Corp. as its Chief Executive Officer, President, and Chief Scientific Officer. There he successfully created a new type of peptide based drug, built an FDA approved manufacturing facility, and brought this drug into clinical trials under INDs with the US FDA. He then took the positions as Senior Vice President for Graduate and Professional Education and Senior Vice President for Graduate Academic Affairs at Touro College and the Touro University System. Dr. Hirschman is one of the three founders of Touro College and the Touro University System and served as a member of the Board of Directors for more than three decades. He initiated and negotiated the purchase of New York Medical College by Touro College. During the past five years Dr. Hirschman has been a consultant to educational institutions, biotechnology companies and biotechnology investment funds, especially to Sunrise Securities Corporation.
- Samuel Zentman
-
Samuel Zentman毕业于韦恩州立大学和密歇根大学，拥有复数分析博士学位。他曾是底特律大学多个部门的数学教授。曾任美国汽车公司系统分析师、工程计算机中心经理、企业计算机中心主任。Zentman博士曾是曼哈顿纺织公司的首席财务官和首席执行官，该公司是纽约市的一家私营出口公司。他曾是多家科技和医疗初创公司的董事会成员，包括：NeuroMedical Systems Inc.、Amplification Technologies，Inc.、Power Safe Technology Corp和Hinson Hale Medical Technologies Inc.。Zentman博士目前是橡子能源的董事会成员，并且是审计委员会主席、提名委员会和薪酬委员会成员。Zentman博士在与早期医疗和技术公司打交道方面拥有丰富的经验。他还担任几个致力于美国和国外教育质量的全国性非营利组织的董事会主席。Greenland Mines Ltd认为，Zentman博士有资格担任Greenland Mines Ltd的董事会成员，因为他在商业管理、公共和私营公司财务方面拥有数十年的专业知识，他对医疗技术的洞察力，以及他的全球人脉和业务关系。
Samuel Zentman graduated from Wayne State University and the University of Michigan and holds a Ph.D. doctorate in Complex Analysis. He was a Mathematics professor at several divisions of the University of Detroit. And worked as a systems analyst, manager of Engineering Computer Center, and director of the Corporate Computer Center of American Motors Corporation. Dr. Zentman was the CFO and then CEO of Manhattan Textile Corporation, a privately held export firm in New York city. He was a Board member of several Tech and Medical start ups including: Neuromedical Systems Inc., Amplification Technologies, Inc., Power Safe Technology Corp, and Hinson Hale Medical Technologies Inc. Dr. Zentman is currently a Board member of Acorn Energy where he has served for over the past 15 years, and is the Chairman of the Audit Committee, and member of the Nominating Committee and Compensation Committee. Dr. Zentman has extensive experience in dealing with early stage medical and technology companies. He also serves as the Chairman of the Board of several national non profits organizations devoted to the quality of education in the U.S. and abroad. - Samuel Zentman毕业于韦恩州立大学和密歇根大学，拥有复数分析博士学位。他曾是底特律大学多个部门的数学教授。曾任美国汽车公司系统分析师、工程计算机中心经理、企业计算机中心主任。Zentman博士曾是曼哈顿纺织公司的首席财务官和首席执行官，该公司是纽约市的一家私营出口公司。他曾是多家科技和医疗初创公司的董事会成员，包括：NeuroMedical Systems Inc.、Amplification Technologies，Inc.、Power Safe Technology Corp和Hinson Hale Medical Technologies Inc.。Zentman博士目前是橡子能源的董事会成员，并且是审计委员会主席、提名委员会和薪酬委员会成员。Zentman博士在与早期医疗和技术公司打交道方面拥有丰富的经验。他还担任几个致力于美国和国外教育质量的全国性非营利组织的董事会主席。Greenland Mines Ltd认为，Zentman博士有资格担任Greenland Mines Ltd的董事会成员，因为他在商业管理、公共和私营公司财务方面拥有数十年的专业知识，他对医疗技术的洞察力，以及他的全球人脉和业务关系。
- Samuel Zentman graduated from Wayne State University and the University of Michigan and holds a Ph.D. doctorate in Complex Analysis. He was a Mathematics professor at several divisions of the University of Detroit. And worked as a systems analyst, manager of Engineering Computer Center, and director of the Corporate Computer Center of American Motors Corporation. Dr. Zentman was the CFO and then CEO of Manhattan Textile Corporation, a privately held export firm in New York city. He was a Board member of several Tech and Medical start ups including: Neuromedical Systems Inc., Amplification Technologies, Inc., Power Safe Technology Corp, and Hinson Hale Medical Technologies Inc. Dr. Zentman is currently a Board member of Acorn Energy where he has served for over the past 15 years, and is the Chairman of the Audit Committee, and member of the Nominating Committee and Compensation Committee. Dr. Zentman has extensive experience in dealing with early stage medical and technology companies. He also serves as the Chairman of the Board of several national non profits organizations devoted to the quality of education in the U.S. and abroad.
高管简历
中英对照 | 中文 | 英文- Joseph Sinkule
Joseph Sinkule已经从一名化学家、科学家和临床研究人员发展成为一名成功的商人和连续创业者。2015年，他创立并一直担任ANEW Oncology，Inc.的首席执行官和董事长。2022年，Sinkule博士成为收购ANEW Oncology的ANEW MEDICAL的董事长和首席执行官。1976年获得美国内布拉斯加州大学化学学士学位，1980年获得美国内布拉斯加州大学医学中心药学、药理学和药代动力学（Pharm.D.）博士学位。他的博士后培训是在田纳西州孟菲斯的圣裘德儿童研究医院，他在芝加哥大学和密歇根大学担任过多个学术职位。他于1990年加入制药和生物技术行业，曾担任关键管理层和高级董事职务超过15年，其中包括Techniclone International的高级副总裁和董事会成员，该公司是一家在33岁时在纳斯达克上市的生物技术公司。他创立、担任CEO，并在两家生物制药公司的董事会任职—— 2005年至2008年的Virionics Corporation和2008年至2012年的Apthera，Inc.。他于2015年创立并担任ANEW Oncology，Inc.的首席执行官和董事会主席，该公司于2019年成为ANEW MEDICAL，INC.。Joseph在过去40年里一直参与药物开发。在过去的18年里，他一直是细胞和基因治疗领域多家公司和学者的顾问和顾问。Sinkule博士还是公司治理委员会主席。Sinkule博士因其丰富的管理经验、药物开发经验、商业、金融和创业经验，以及国际人脉和关系，有资格担任Greenland Mines Ltd的董事会成员。
Joseph Sinkule has evolved from a chemist, scientist and clinical researcher into a successful businessman and serial entrepreneur. In 2015, he founded and has served as Chief Executive Officer and Chairman of Anew Oncology, Inc. In 2022, Dr. Sinkule became the Chairman and Chief Executive Officer of ANEW MEDICAL which acquired Anew Oncology. He received his B.S in Chemistry from the University of Nebraska in 1976 and a doctorate in pharmacy, pharmacology, and pharmacokinetics (Pharm.D.) from University of Nebraska Medical Center in 1980. His post doctoral training was at St. Jude Children's Research Hospital in Memphis, TN and he held several academic positions at the University of Chicago and the University of Michigan. He joined the pharmaceutical and biotechnology industry in 1990 and held key management and senior directorship positions for over 15 years including Senior Vice President and Board member of Techniclone International, a Nasdaq listed biotech company at the age of 33 years old. He founded, was the CEO, and served on the Board of two biopharmaceutical companies — Virionics Corporation from 2005 2008 and Apthera, Inc. from 2008 2012. He founded and served as CEO and Chairman of the Board of Anew Oncology, Inc. in 2015, which became ANEW MEDICAL, INC. in 2019. Joseph has been involved with drug development for the past 40 years. He has been a consultant and advisor to several companies and academics in the fields of cell and gene therapy for the past 18 years. Dr. Sinkule is also the Chair of the Corporate Governance Committee.- Joseph Sinkule已经从一名化学家、科学家和临床研究人员发展成为一名成功的商人和连续创业者。2015年，他创立并一直担任ANEW Oncology，Inc.的首席执行官和董事长。2022年，Sinkule博士成为收购ANEW Oncology的ANEW MEDICAL的董事长和首席执行官。1976年获得美国内布拉斯加州大学化学学士学位，1980年获得美国内布拉斯加州大学医学中心药学、药理学和药代动力学（Pharm.D.）博士学位。他的博士后培训是在田纳西州孟菲斯的圣裘德儿童研究医院，他在芝加哥大学和密歇根大学担任过多个学术职位。他于1990年加入制药和生物技术行业，曾担任关键管理层和高级董事职务超过15年，其中包括Techniclone International的高级副总裁和董事会成员，该公司是一家在33岁时在纳斯达克上市的生物技术公司。他创立、担任CEO，并在两家生物制药公司的董事会任职—— 2005年至2008年的Virionics Corporation和2008年至2012年的Apthera，Inc.。他于2015年创立并担任ANEW Oncology，Inc.的首席执行官和董事会主席，该公司于2019年成为ANEW MEDICAL，INC.。Joseph在过去40年里一直参与药物开发。在过去的18年里，他一直是细胞和基因治疗领域多家公司和学者的顾问和顾问。Sinkule博士还是公司治理委员会主席。Sinkule博士因其丰富的管理经验、药物开发经验、商业、金融和创业经验，以及国际人脉和关系，有资格担任Greenland Mines Ltd的董事会成员。
- Joseph Sinkule has evolved from a chemist, scientist and clinical researcher into a successful businessman and serial entrepreneur. In 2015, he founded and has served as Chief Executive Officer and Chairman of Anew Oncology, Inc. In 2022, Dr. Sinkule became the Chairman and Chief Executive Officer of ANEW MEDICAL which acquired Anew Oncology. He received his B.S in Chemistry from the University of Nebraska in 1976 and a doctorate in pharmacy, pharmacology, and pharmacokinetics (Pharm.D.) from University of Nebraska Medical Center in 1980. His post doctoral training was at St. Jude Children's Research Hospital in Memphis, TN and he held several academic positions at the University of Chicago and the University of Michigan. He joined the pharmaceutical and biotechnology industry in 1990 and held key management and senior directorship positions for over 15 years including Senior Vice President and Board member of Techniclone International, a Nasdaq listed biotech company at the age of 33 years old. He founded, was the CEO, and served on the Board of two biopharmaceutical companies — Virionics Corporation from 2005 2008 and Apthera, Inc. from 2008 2012. He founded and served as CEO and Chairman of the Board of Anew Oncology, Inc. in 2015, which became ANEW MEDICAL, INC. in 2019. Joseph has been involved with drug development for the past 40 years. He has been a consultant and advisor to several companies and academics in the fields of cell and gene therapy for the past 18 years. Dr. Sinkule is also the Chair of the Corporate Governance Committee.
- Jeffrey LeBlanc
杰弗里·勒布朗（Jeffrey LeBlanc）在管理金融运营、投资、为世界500强企业提供咨询以及发起新企业方面拥有超过20年的经验。他是特殊目的收购公司WinVest Acquisition Corp.（股票代码：WINV）的共同创始人。在Winvest之前，勒布朗先生推出了Out of Print，这是一个直接面向消费者的商品平台，于2017年被企鹅兰登书屋收购。他此前曾在Greenlight Capital和GE Capital担任投资职务，并在麦肯锡公司开始了他的职业生涯。勒布朗先生此前曾在Riot New Media Group和Books for Africa的董事会任职。他获得了哈佛商学院的MBA学位和麻省理工学院的化学工程学士学位。
Jeffrey LeBlanc has over 20 years of experience in managing financial operations, investing, advising Fortune 500 companies, and launching new ventures. He is the co founder of Winvest Acquisition Corp. (Ticker: WINV), a special purpose acquisition company. Prior to Winvest, Mr. LeBlanc launched Out of Print, a direct to consumer merchandise platform that was acquired by Penguin Random House in 2017. He previously held investment roles at Greenlight Capital and GE Capital, and started his career at McKinsey and Co. Mr. LeBlanc previously served on the Boards of Riot New Media Group and Books For Africa. He received an MBA from Harvard Business School and a BS in Chemical Engineering from MIT.- 杰弗里·勒布朗（Jeffrey LeBlanc）在管理金融运营、投资、为世界500强企业提供咨询以及发起新企业方面拥有超过20年的经验。他是特殊目的收购公司WinVest Acquisition Corp.（股票代码：WINV）的共同创始人。在Winvest之前，勒布朗先生推出了Out of Print，这是一个直接面向消费者的商品平台，于2017年被企鹅兰登书屋收购。他此前曾在Greenlight Capital和GE Capital担任投资职务，并在麦肯锡公司开始了他的职业生涯。勒布朗先生此前曾在Riot New Media Group和Books for Africa的董事会任职。他获得了哈佛商学院的MBA学位和麻省理工学院的化学工程学士学位。
- Jeffrey LeBlanc has over 20 years of experience in managing financial operations, investing, advising Fortune 500 companies, and launching new ventures. He is the co founder of Winvest Acquisition Corp. (Ticker: WINV), a special purpose acquisition company. Prior to Winvest, Mr. LeBlanc launched Out of Print, a direct to consumer merchandise platform that was acquired by Penguin Random House in 2017. He previously held investment roles at Greenlight Capital and GE Capital, and started his career at McKinsey and Co. Mr. LeBlanc previously served on the Boards of Riot New Media Group and Books For Africa. He received an MBA from Harvard Business School and a BS in Chemical Engineering from MIT.